Results 21 to 30 of about 1,706,856 (229)
Infiltrative Lung Diseases: Complications of Novel Antineoplastic Agents in Patients with Hematological Malignancies [PDF]
Infiltrative lung disease is a well-known complication of antineoplastic agents in patients with hematological malignancies. Novel agents are constantly being added to available treatments.
Bobbak Vahid, Paul E Marik
doaj +2 more sources
Data on drug–drug interactions (DDI) of antineoplastic drugs with anticoagulants is scarce. We aim to evaluate factors associated with DDI of antineoplastic and supportive care drugs with anticoagulants resulting in modification of pharmacokinetics of ...
Érique José F. Peixoto de Miranda MD, PhD +6 more
doaj +2 more sources
Objective: Resistance to anticancer agents ensures a poor prognosis in patients with lung cancer. Metformin could enhance the anticancer effects of standard antineoplastic agents [traditional chemotherapy drugs, epidermal growth factor receptor tyrosine ...
Xiaofeng Luo +8 more
doaj +1 more source
Adherence to oral antineoplastic agents, an overview and meta-analysis. [PDF]
Background The use of oral antineoplastic therapies has accelerated in recent years. Non-supervised administration of oncological therapies introduces uncertainty in regard to adherence.
Mourath D, Fohlin H.
europepmc +2 more sources
Background Permeability of antineoplastic agents through medical gloves is an important factor that must be considered for the appropriate selection of gloves.
Toyohito Oriyama +6 more
doaj +1 more source
Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents-updated MASCC/ESMO consensus recommendation. [PDF]
PurposeOur goal was to identify new anticancer agents approved by the US Food and Drug Administration (FDA) and the European Medical Agency (EMA) since the 2016 MASCC/ESMO antiemetic update and classify their emetic potential.MethodsThe MASCC/ESMO Expert
Jordan K +7 more
europepmc +2 more sources
DENDROGENIN A AND ANTINEOPLASTIC AGENTS FOR THE TREATMENT OF CHEMOSENSITIVE OR CHEMORESISTANT TUMORS
Dendrogenin A and antineoplastic agents for the treatment of chemosensitive or chemoresistant tumors. The invention concerns a kit-of-parts comprising 5α-hydroxy-6&bgr;-[2-(1H-imidazol-4-yl)ethylamino]cholestan-3&bgr;-ol (Dendrogenin A) or a ...
Silvente-Poirot, Sandrine +4 more
core +10 more sources
Objectives: Non-small cell lung cancer (NSCLC) accounts for 75–85% of all lung cancer diagnoses. This meta-analysis sought to estimate the overall survival (OS) of NSCLC based on randomized control trials which had compared docetaxel with kinase ...
Chaitra Nagaraju +10 more
doaj +1 more source
A Review of Antineoplastic Agents Associated Nephrotoxicity, an Understood Complication [PDF]
In the recent decades, the survival of children with cancer has improved dramatically. This improvement is due to use of different chemotherapeutic agents, but the majority of these drugs have kidney toxicities.
Hashemieh, Mozhgan
core +1 more source
Antineoplastic Agents Targeting Sphingolipid Pathways
Emerging studies in the enigmatic area of bioactive lipids have made many exciting new discoveries in recent years. Once thought to play a strictly structural role in cellular function, it has since been determined that sphingolipids and their ...
Alexander Kroll +4 more
doaj +1 more source

